AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01663805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
Study NCT00667589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea 40% cream
Description: urea 40% cream applied twice per day to affected areas
Study NCT00667589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinonide 0.05% cream
Description: fluocinonide 0.05% cream applied twice per day to affected areas
Study NCT00667589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tazarotene 0.1% cream
Description: tazarotene 0.1% cream applied twice per day to affected areas
Study NCT00667589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bland emollient cream (Udderly smooth® Udder Cream)
Description: bland emollient cream applied twice per day to affected areas
Study NCT00711204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil Hydrochloride (Aricept)
Description: 5mg (or 10mg) tablet, once daily, with a full glass of water.
Study NCT00711204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride (Aricept)
Description: 5mg (or 10mg) tablet, once daily, with a full glass of water.
Study NCT01893762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
Study NCT01893762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anaerobic exercise
Description: Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
Study NCT03907956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling with Fascial Winding Technique
Description: For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp.
Study NCT01433770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amevive
Description: Alefacept 15mg subcutaneous; once a week for 12 weeks
Study NCT04604093 — intervention group
Intervention type: DEVICE
Intervention: SMBG Meter
Description: Self Monitoring Blood Glucose Meter
Study NCT04604093 — intervention group
Intervention type: DEVICE
Intervention: FreeStyle Libre 2 System
Description: The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
Study NCT03280030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 50 mg \[two 25 mg capsules\] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
Study NCT03280030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
Study NCT02194686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: One tablet (100 mg) twice per day for 12 weeks
Study NCT02194686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Placebo
Description: One tablet twice per day for 12 weeks
Study NCT04095936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Subcutaneous administration of 0 to 20ug/kg for 6 months
Study NCT01572688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: powder for injection, 200mg/m2, uses after reconstituted within 24 hours
Study NCT03220555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Description: Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
Study NCT03220555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLAPATCH (lidocaine, prilocaine)
Description: The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
Study NCT00537082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Administered orally once daily for 6 months
Study NCT00537082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 6 months
Study NCT00655746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + Omeprazole
Description: Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
Study NCT04241718 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aquadex FlexFlow System and BVA-100
Description: Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
Study NCT03819205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
Study NCT04060745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cooling using a water-perfused vest
Description: BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed
Study NCT04060745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermoneutrality
Description: In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
Study NCT03126734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Massage course
Description: Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually.
Study NCT01939275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: copper Cu 64-DOTA-trastuzumab
Description: Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
Study NCT01939275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
Study NCT01939275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01939275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
Study NCT04289298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage-A
Description: Therapist will encourage participants to engage in physical and social activities that are pleasurable or rewarding. Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
Study NCT04289298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and utilizing Engage-A therapy
Description: Therapist will be trained in Engage-A therapy and given supervision while utilizing this therapy.
Study NCT03979989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR capsule
Description: Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
Study NCT03979989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole capsule
Description: Omeprazole capsule containing 40 mg omeprazole.
Study NCT03832452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat (Treatment A)
Description: 2000 and 4000 mg; hard capsules for oral administration
Study NCT03832452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard capsules for oral administration
Study NCT03832452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg; film-coated tablets for oral administration
Study NCT03832452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat (Treatment B)
Description: 1000 mg; hard capsules for oral administration
Study NCT03832452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat (Treatment C)
Description: 4000 mg; hard capsules for oral administration
Study NCT01797185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1104 modified dose regimen I
Description: Subjects who exited study CLR_09_21
Study NCT01797185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1104 modified dose regimen II
Description: Subjects who received prior treatment regimen I
Study NCT01797185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1104 modified dose regimen III
Description: Subjects who received no prior treatment regimen
Study NCT03302663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan
Description: Addition of advanced imaging sequences for fetal MRI
Study NCT01684605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP 60μg
Description: Administrated NESP 60μg once intravenously
Study NCT01684605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-11101 60μg
Description: Administrated CKD-11101 60μg once intravenously
Study NCT00676039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gen-Citalopram
Description: Gen-Citalopram 40 mg (Genpharm, Generic)
Study NCT00676039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor XR
Description: Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
Study NCT04981054 — intervention group
Intervention type: PROCEDURE
Intervention: Cystocele repair
Description: Repair of endopelvic fascia and anterior colporrhaphy
Study NCT00768859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, trastuzumab and carboplatin
Description: paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
Study NCT03940677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain MRI
Description: 3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
Study NCT03940677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TMS-EEG
Description: Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
Study NCT03940677 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral and cognitive battery
Description: Emotional, attentional and behavioral assessment using predefine scales and measures
Study NCT03940677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluation and clinical scales
Description: Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
Study NCT03549260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIB003
Description: LIB003 or placebo
Study NCT03400189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulthiame
Description: Single dose (50, 100, 200 mg)
Study NCT02971189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Librata Endometrial Ablation
Description: The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
Study NCT00138294 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: live attenuated and inactivated influenza vaccines
Description: Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
Study NCT00138294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: live attenuated and inactivated influenza vaccines
Description: Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
Study NCT03986541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
Study NCT05474209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes
Description: Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months
Study NCT05000437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: 3x/week high intensity interval training for 12 weeks
Study NCT00530075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gusperimus
Description: SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
Study NCT04015687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-881
Description: Supplied as uncoated tablets.
Study NCT04015687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Supplied as tablets of LAMICTAL® or generic equivalent.
Study NCT01622335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
Study NCT01622335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia with oxygen
Description: General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
Study NCT02410876 — intervention group
Intervention type: PROCEDURE
Intervention: Bladder biopsy
Description: Small biopsy of the bladder is taken with cold-cup tongs.
Study NCT02410876 — intervention group
Intervention type: PROCEDURE
Intervention: Urodynamic study
Description: Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
Study NCT00466167 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexol Immediate Release
Study NCT00466167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03599193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Lotion, 0.1%
Description: DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
Study NCT03599193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.1%
Description: Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
Study NCT03932058 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
Study NCT02421822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitwits office tool and games
Description: Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
Study NCT03596567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib single 100 mg dose in normal healthy subjects
Description: A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study NCT03596567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib single 100 mg dose in moderate renal impairment subjects
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study NCT03596567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib single 100 mg dose in severe renal impairment subjects
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study NCT02684747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Transfusion
Description: Participants will receive autologous transfusion on Day 21
Study NCT02684747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Normal Saline (Placebo)
Description: Participants will receive saline on Day 21
Study NCT04418297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-G20
Description: oral tablet
Study NCT04418297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT04210947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 rolls per minute(30RPM)
Description: Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
Study NCT04210947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 rolls per minute(15RPM)
Description: Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
Study NCT04210947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-determined
Description: Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
Study NCT03598998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03598998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Given IV